Association between aberrant dynein cytoplasmic 1 light intermediate chain 1 expression levels, mucins and
chemosensitivity in colorectal cancer

Chang,Chun‑Chao; Chao,Kuo‑Ching; Huang,Chi‑Jung; Hung,Chih‑Sheng; Wang,Yen‑Chieh

doi:10.3892/mmr.2020.11086

Association between aberrant dynein cytoplasmic 1 light intermediate chain 1 expression levels, mucins and chemosensitivity in colorectal cancer

Authors:
- Chun‑Chao Chang
- Kuo‑Ching Chao
- Chi‑Jung Huang
- Chih‑Sheng Hung
- Yen‑Chieh Wang
View Affiliations

Affiliations: Division of Gastroenterology and Hepatology, Department of Internal Medicine, Taipei Medical University Hospital, Taipei 11031, Taiwan, R.O.C., Department of Medical Research, Cathay General Hospital, Taipei 10630, Taiwan, R.O.C., Division of Gastroenterology, Department of Internal Medicine, Cathay General Hospital, Taipei 10630, Taiwan, R.O.C., School of Medicine, College of Medicine, Fu Jen Catholic University, New Taipei 24205, Taiwan, R.O.C.
Published online on: April 22, 2020 https://doi.org/10.3892/mmr.2020.11086
Pages: 185-192
Copyright: © Chang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Dynein transport along the cytoskeletal microtubules towards the minus end is essential for cell division, cell migration and other basic cellular functions. Dynein cytoplasmic 1 light intermediate chain 1 (DYNC1LI1) has been previously associated with pancreatic ductal adenocarcinoma, hepatocellular carcinoma and prostate cancer. Cytoskeletal structures are involved in the regulation of the mucosal barrier integrity. Thus, improving our understanding of the molecular mechanisms that regulate the mucosal barrier is critical for cancer management and treatment. The present study aimed to investigate DYNC1LI1 expression in colorectal cancer (CRC) tissues. The American Joint Committee on Cancer Stage II CRC cell line LS 174T was used to determine the association between the cellular expression levels of DYNC1LI1 and different types of mucin (MUC) by reverse transcription‑quantitative PCR. The role of DYNC1LI1 in cell chemosensitivity and proliferation was also evaluated in the presence of the DNA analog 5‑fluorouracil (5‑FU) or the platinum‑based drug, oxaliplatin by the MTT assay. LS 174T cells with decreased expression levels of DYNC1LI1 were discovered to be more sensitive to 5‑FU compared with LS 174T cells with endogenous DYNC1LI1 expression levels. Moreover, LS 174T cells transfected with short hairpin RNA targeting DYNC1LI1 were associated with low MUC1 and high MUC2, MUC4 and MUC5AC expression levels. Notably, the CRC cells with low MUC1 expression levels and high expression levels of the other MUCs (MUC2, MU4 and MUC5AC) were shown to benefit from 5‑FU treatment. In conclusion, the findings of the present study have suggested that DYNC1LI1 expression may be significantly associated with MUC expression levels and may be used to predict the chemotherapeutic efficiency. However, additional functional studies and clinical reports are required for an improved understanding of the significance of these molecular interactions in tumorigenesis.

View Figures

View References

1	Singh R, Kapur N, Mir H, Singh N, Lillard JW Jr and Singh S: CXCR6-CXCL16 axis promotes prostate cancer by mediating cytoskeleton rearrangement via Ezrin activation and alphavbeta3 integrin clustering. Oncotarget. 7:7343–7353. 2016. View Article : Google Scholar : PubMed/NCBI
2	Wu K, Zhang X, Li F, Xiao D, Hou Y, Zhu S, Liu D, Ye X, Ye M, Yang J, et al: Frequent alterations in cytoskeleton remodelling genes in primary and metastatic lung adenocarcinomas. Nat Commun. 6:101312015. View Article : Google Scholar : PubMed/NCBI
3	Kuijpers M, van de Willige D, Freal A, Chazeau A, Franker MA, Hofenk J, Rodrigues RJ, Kapitein LC, Akhmanova A, Jaarsma D and Hoogenraad CC: Dynein regulator NDEL1 controls polarized cargo transport at the axon initial segment. Neuron. 89:461–471. 2016. View Article : Google Scholar : PubMed/NCBI
4	McKenney RJ, Huynh W, Tanenbaum ME, Bhabha G and Vale RD: Activation of cytoplasmic dynein motility by dynactin-cargo adapter complexes. Science. 345:337–341. 2014. View Article : Google Scholar : PubMed/NCBI
5	McLaughlin RT, Diehl MR and Kolomeisky AB: Collective dynamics of processive cytoskeletal motors. Soft Matter. 12:14–21. 2015. View Article : Google Scholar
6	Johnson JL, Hamm-Alvarez S, Payne G, Sancar GB, Rajagopalan KV and Sancar A: Identification of the second chromophore of Escherichia coli and yeast DNA photolyases as 5,10-methenyltetrahydrofolate. Proc Natl Acad Sci USA. 85:2046–2050. 1988. View Article : Google Scholar : PubMed/NCBI
7	Schnaeker EM, Ossig R, Ludwig T, Dreier R, Oberleithner H, Wilhelmi M and Schneider SW: Microtubule-dependent matrix metalloproteinase-2/matrix metalloproteinase-9 exocytosis: Prerequisite in human melanoma cell invasion. Cancer Res. 64:8924–8931. 2004. View Article : Google Scholar : PubMed/NCBI
8	Vidulescu C, Clejan S and O'Connor KC: Vesicle traffic through intercellular bridges in DU 145 human prostate cancer cells. J Cell Mol Med. 8:388–396. 2004. View Article : Google Scholar : PubMed/NCBI
9	Yoon SO, Shin S and Mercurio AM: Hypoxia stimulates carcinoma invasion by stabilizing microtubules and promoting the Rab11 trafficking of the alpha6beta4 integrin. Cancer Res. 65:2761–2769. 2005. View Article : Google Scholar : PubMed/NCBI
10	Izidoro-Toledo TC, Borges AC, Araujo DD, Mazzi DP, Nascimento Junior FO, Sousa JF, Alves CP, Paiva AP, Trindade DM, Patussi EV, et al: A myosin-Va tail fragment sequesters dynein light chains leading to apoptosis in melanoma cells. Cell Death Dis. 4:e5472013. View Article : Google Scholar : PubMed/NCBI
11	Jiang J, Yu L, Huang X, Chen X, Li D, Zhang Y, Tang L and Zhao S: Identification of two novel human dynein light chain genes, DNLC2A and DNLC2B, and their expression changes in hepatocellular carcinoma tissues from 68 Chinese patients. Gene. 281:103–113. 2001. View Article : Google Scholar : PubMed/NCBI
12	Dong H, Zhang H, Liang J, Yan H, Chen Y, Shen Y, Kong Y, Wang S, Zhao G and Jin W: Digital karyotyping reveals probable target genes at 7q21.3 locus in hepatocellular carcinoma. BMC Med Genomics. 4:602011. View Article : Google Scholar : PubMed/NCBI
13	Weeks ME, Hariharan D, Petronijevic L, Radon TP, Whiteman HJ, Kocher HM, Timms JF, Lemoine NR and Crnogorac-Jurcevic T: Analysis of the urine proteome in patients with pancreatic ductal adenocarcinoma. Proteomics Clin Appl. 2:1047–1057. 2008. View Article : Google Scholar : PubMed/NCBI
14	Zhao H, Pflug BR, Lai X and Wang M: Pyruvate dehydrogenase alpha 1 as a target of omega-3 polyunsaturated fatty acids in human prostate cancer through a global phosphoproteomic analysis. Proteomics. 16:2419–2431. 2016. View Article : Google Scholar : PubMed/NCBI
15	Parsons CL: The role of the urinary epithelium in the pathogenesis of interstitial cystitis/prostatitis/urethritis. Urology. 69:9–16. 2007. View Article : Google Scholar : PubMed/NCBI
16	Petersson J, Schreiber O, Hansson GC, Gendler SJ, Velcich A, Lundberg JO, Roos S, Holm L and Phillipson M: Importance and regulation of the colonic mucus barrier in a mouse model of colitis. Am J Physiol Gastrointest Liver Physiol. 300:G327–G333. 2011. View Article : Google Scholar : PubMed/NCBI
17	Betge J, Schneider NI, Harbaum L, Pollheimer MJ, Lindtner RA, Kornprat P, Ebert MP and Langner C: MUC1, MUC2, MUC5AC, and MUC6 in colorectal cancer: Expression profiles and clinical significance. Virchows Arch. 469:255–265. 2016. View Article : Google Scholar : PubMed/NCBI
18	Byrd JC and Bresalier RS: Mucins and mucin binding proteins in colorectal cancer. Cancer Metastasis Rev. 23:77–99. 2004. View Article : Google Scholar : PubMed/NCBI
19	Kufe DW: Mucins in cancer: function, prognosis and therapy. Nat Rev Cancer. 9:874–885. 2009. View Article : Google Scholar : PubMed/NCBI
20	Ivanov AI, Parkos CA and Nusrat A: Cytoskeletal regulation of epithelial barrier function during inflammation. Am J Pathol. 177:512–524. 2010. View Article : Google Scholar : PubMed/NCBI
21	Bu XD, Li N, Tian XQ and Huang PL: Caco-2 and LS174T cell lines provide different models for studying mucin expression in colon cancer. Tissue Cell. 43:201–206. 2011. View Article : Google Scholar : PubMed/NCBI
22	Du J, Zheng X, Cai S, Zhu Z, Tan J, Hu B, Huang Z and Jiao H: MicroRNA506 participates in pancreatic cancer pathogenesis by targeting PIM3. Mol Med Rep. 12:5121–5126. 2015. View Article : Google Scholar : PubMed/NCBI
23	Ohuchida K, Mizumoto K, Yamada D, Fujii K, Ishikawa N, Konomi H, Nagai E, Yamaguchi K, Tsuneyoshi M and Tanaka M: Quantitative analysis of MUC1 and MUC5AC mRNA in pancreatic juice for preoperative diagnosis of pancreatic cancer. Int J Cancer. 118:405–411. 2006. View Article : Google Scholar : PubMed/NCBI
24	Baratelli C, Zichi C, Di Maio M, Brizzi MP, Sonetto C, Scagliotti GV and Tampellini M: A systematic review of the safety profile of the different combinations of fluoropyrimidines and oxaliplatin in the treatment of colorectal cancer patients. Crit Rev Oncol Hematol. 122:21–29. 2018. View Article : Google Scholar : PubMed/NCBI
25	Park SH, Sung JY, Han SH, Baek JH, Oh JH, Bang SM, Cho EK, Shin DB and Lee JH: Oxaliplatin, folinic acid and 5-fluorouracil (FOLFOX-4) combination chemotherapy as second-line treatment in advanced colorectal cancer patients with irinotecan failure: A Korean single-center experience. Jpn J Clin Oncol. 35:531–535. 2005. View Article : Google Scholar : PubMed/NCBI
26	Fearnhead NS, Wilding JL and Bodmer WF: Genetics of colorectal cancer: Hereditary aspects and overview of colorectal tumorigenesis. Br Med Bull. 64:27–43. 2002. View Article : Google Scholar : PubMed/NCBI
27	van Ree JH, Nam HJ and van Deursen JM: Mitotic kinase cascades orchestrating timely disjunction and movement of centrosomes maintain chromosomal stability and prevent cancer. Chromosome Res. 24:67–76. 2016. View Article : Google Scholar : PubMed/NCBI
28	Chang CC, Chien CC, Yang SH, Chen SH and Huang CJ: Identification and clinical correlation of decreased expression of cytoplasmic dynein heavy chain 1 in patients with colorectal cancer. Clin Mol Medicine. 1:6–10. 2008.
29	Holmberg FEO, Pedersen J, Jorgensen P, Soendergaard C, Jensen KB and Nielsen OH: Intestinal barrier integrity and inflammatory bowel disease: Stem cell-based approaches to regenerate the barrier. J Tissue Eng Regen Med. 12:923–935. 2018. View Article : Google Scholar : PubMed/NCBI
30	Gouyer V, Dubuquoy L, Robbe-Masselot C, Neut C, Singer E, Plet S, Geboes K, Desreumaux P, Gottrand F and Desseyn JL: Delivery of a mucin domain enriched in cysteine residues strengthens the intestinal mucous barrier. Sci Rep. 5:95772015. View Article : Google Scholar : PubMed/NCBI
31	Tadesse S, Corner G, Dhima E, Houston M, Guha C, Augenlicht L and Velcich A: MUC2 mucin deficiency alters inflammatory and metabolic pathways in the mouse intestinal mucosa. Oncotarget. 8:71456–71470. 2017. View Article : Google Scholar : PubMed/NCBI
32	McAuley JL, Linden SK, Png CW, King RM, Pennington HL, Gendler SJ, Florin TH, Hill GR, Korolik V and McGuckin MA: MUC1 cell surface mucin is a critical element of the mucosal barrier to infection. J Clin Invest. 117:2313–2324. 2007. View Article : Google Scholar : PubMed/NCBI
33	Ren J, Agata N, Chen D, Li Y, Yu WH, Huang L, Raina D, Chen W, Kharbanda S and Kufe D: Human MUC1 carcinoma-associated protein confers resistance to genotoxic anticancer agents. Cancer Cell. 5:163–175. 2004. View Article : Google Scholar : PubMed/NCBI
34	Cozzi PJ, Wang J, Delprado W, Perkins AC, Allen BJ, Russell PJ and Li Y: MUC1, MUC2, MUC4, MUC5AC and MUC6 expression in the progression of prostate cancer. Clin Exp Metastasis. 22:565–573. 2005. View Article : Google Scholar : PubMed/NCBI
35	Morrison C, Merati K, Marsh WL Jr, De Lott L, Cohn DE, Young G and Frankel WL: The mucin expression profile of endometrial carcinoma and correlation with clinical-pathologic parameters. Appl Immunohistochem Mol Morphol. 15:426–431. 2007. View Article : Google Scholar : PubMed/NCBI
36	Handra-Luca A, Lamas G, Bertrand JC and Fouret P: MUC1, MUC2, MUC4, and MUC5AC expression in salivary gland mucoepidermoid carcinoma: Diagnostic and prognostic implications. Am J Surg Pathol. 29:881–889. 2005. View Article : Google Scholar : PubMed/NCBI
37	Hosseini S, Bananzadeh AM, Salek R, Zare-Bandamiri M, Kermani AT and Mohammadianpanah M: Prognostic significance of mucinous histologic subtype on oncologic outcomes in patients with colorectal cancer. Ann Coloproctol. 33:57–63. 2017. View Article : Google Scholar : PubMed/NCBI
38	Purdie CA and Piris J: Histopathological grade, mucinous differentiation and DNA ploidy in relation to prognosis in colorectal carcinoma. Histopathology. 36:121–126. 2000. View Article : Google Scholar : PubMed/NCBI
39	Xie L, Villeneuve PJ and Shaw A: Survival of patients diagnosed with either colorectal mucinous or non-mucinous adenocarcinoma: A population-based study in Canada. Int J Oncol. 34:1109–1115. 2009. View Article : Google Scholar : PubMed/NCBI
40	Niv Y and Rokkas T: Mucin expression in colorectal cancer (CRC): Systematic review and meta-analysis. J Clin Gastroenterol. 53:434–440. 2018. View Article : Google Scholar
41	Gonul II, Cakir A and Sozen S: Immunohistochemical expression profiles of MUC1 and MUC2 mucins in urothelial tumors of bladder. Indian J Pathol Microbiol. 61:350–355. 2018. View Article : Google Scholar : PubMed/NCBI
42	Even I, Reidenbach S, Schlechter T, Berns N, Herold R, Roth W, Krunic D, Riechmann V and Hofmann I: DLIC1, but not DLIC2, is upregulated in colon cancer and this contributes to proliferative overgrowth and migratory characteristics of cancer cells. FEBS J. 286:803–820. 2019. View Article : Google Scholar : PubMed/NCBI
43	Kalra AV and Campbell RB: Mucin impedes cytotoxic effect of 5-FU against growth of human pancreatic cancer cells: Overcoming cellular barriers for therapeutic gain. Br J Cancer. 97:910–918. 2007. View Article : Google Scholar : PubMed/NCBI